Live
- PM Vidya Lakshmi Scheme to Help Underprivileged Students Achieve Their Dreams of Higher Education: MP Brijesh Chowta
- Udupi Cooperative Bank Accused of Loan Fraud
- No more smoking in government office premises
- Google Cloud unveils new initiatives to empower AI startups in India
- Collector Warns of Strict Action if Irregularities Occur in Weighing Process
- WPL 2025: Mumbai Indians release Issy Wong, Humairaa Kaazi, Fatima Jaffer and Priyanka Bala
- People will not forgive Congress for repeatedly insulting Constitution: Kiren Rijiju
- Aid group resumes activities at famine-hit camp in Sudan
- Kishan Reddy Vows to End BRS and Congress Influence in Telangana, Criticizes CM's Governance
- Punjab bypolls: Bittu twisting words for political gains, says Congress nominee
Dr Reddy’s plant gets FDA observations
Shares of Dr Reddys Laboratories dropped nearly 6 per cent Monday after audit of the companys formulations manufacturing plant in Hyderabad was completed by USFDA with 11 observations
Hyderabad: Shares of Dr Reddy's Laboratories dropped nearly 6 per cent Monday after audit of the company's formulations manufacturing plant in Hyderabad was completed by USFDA with 11 observations.
The company's stock tumbled 5.60 per cent to close at Rs 2,616.95 on the BSE. During the day, it tanked 7.81 per cent to Rs 2,555.55. On the NSE, shares dropped 5.57 per cent to close at Rs 2,615.35. On the volume front, 1.13 lakh shares of the company were traded on the BSE and over 18 lakh units on the NSE.
"This is to inform you that the audit of our formulations manufacturing plant- 3 at Bachupally, Hyderabad by USFDA, has been completed. We have been issued a form 483 with 11 observations," Dr Reddy's Labs said in a filing to the BSE on Friday. "We will address them comprehensively within the stipulated timeline," the filing added.
